Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (The BRVO Study)

Trial Profile

Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (The BRVO Study)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Ranibizumab
  • Indications Branch retinal vein occlusion; Central retinal vein occlusion; Retinal oedema
  • Focus Therapeutic Use
  • Acronyms BRVO
  • Most Recent Events

    • 28 Aug 2014 New source identified and integrated (Netherlands Trial Register - NTR3257).
    • 17 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top